About
Andres Isaias is the Chief Executive Officer of RESTEM, a clinical-stage biotechnology company developing off-the-shelf cell therapies for autoimmune, inflammatory, and age-related diseases. He is also publicly identified as Executive Chairman of Restem Group Inc., described in a Diakonos Oncology financing announcement as a biotechnology investment firm. Outside biotech, South Florida real-estate press has also described him as leading Andian Group.
Areas of interest
biotechcell therapyregenerative medicineautoimmune diseaseinflammatory diseaseage-related diseasesoncologyreal estate